On December 21, 2023, the award ceremony for the fifth batch of National "Little Giant" Enterprises, organized by the Ministry of Industry and Information Technology, concluded successfully. Among the selected fifth batch of "Little Giant" enterprises in Guangzhou, totaling 127, Canton Biologics was honored with the title of "Little Giant" Enterprise due to its outstanding technical strength, continuous innovation capability, and leading market share in its niche sector. It is reported that Canton Biologics was the only biologics CDMO company to receive this honor!Little Giant" enterprises refer to those characterized by specialization, refinement, distinctiveness, and innovation. They are pioneering companies focused on niche markets, possessing strong innovation capabilities, high market share, mastery of key core technologies, and excellent quality and efficiency, ranking at the forefront of their respective segments in the industrial chain.

The "Little Giant" designation is widely recognized as one of the most authoritative and highest-level honors in domestic enterprise evaluations.

Receiving this National "Little Giant" Enterprise title less than a year after being awarded the Guangdong Provincial "Specialized and Sophisticated" SME title signifies the high recognition and strong affirmation from government authorities of Canton Biologics' development potential, innovation capability, and professional technical level!

Canton Biologics focuses on biologics CDMSO services and places great emphasis on the independent innovation of its core technologies. Currently, the company possesses internationally leading, fully proprietary commercial animal cell lines, expression systems, and cell culture technologies. It has a complete one-stop CMC development platform for biologics, encompassing cell line construction and development, upstream and downstream process development, analytical method development platforms, and formulation process development. It also possesses technology and quality control method transfer platforms.

In the future, Canton Biologics will continue to leverage its strengths in specialization, refinement, distinctiveness, and innovation, increasing R&D and innovation investments, expanding its competitive advantages, and growing from a "Little Giant" into a true "Giant," creating even greater value for the high-quality development of the pharmaceutical industry in Guangdong Province and the nation.